BeiGene Medical Europe
 Sign in
 
  • Virtual Congress
  • BeiGeneius Webinars
  • BeiGeneius Resources
  • About us
  • beigenemedical.info

Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?

 Back  View
Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?
    07/2021
 View

The expert panel answers questions from the audience on a range of topics related to Waldenström’s macroglobulinemia diagnosis and treatment selection.

 

Rating

Rate this resource

Related resources

Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
 Back

This function is only available for registered users.

BeiGene Medical EU
Welcome to the BeiGene EU Medical Information Website
EuropeWorldItalySpain
I am not a healthcare professional
You are now leaving the website of BeiGene Europe (beigenemedical.info)
You are now leaving the italian website of BeiGene EU.
BeiGene Medical EU
Please check your webbrowser
BeiGene Medical Europe
beigenemedical.eu
  • Virtual Congress
  • About us
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

As part of scientific exchange, BeiGene is providing the most recent abstract(s) accepted by the referenced scientific congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of BeiGene products.
© 2022 BeiGene. All Rights Reserved.
Privacy Policy | Terms of use | Imprint |